Compare Dicks Sporting Goods Inc (DKS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Sanofi SA — how do they compare? Dicks Sporting Goods Inc trades at $203.43 (market cap $18.35B), while Sanofi SA trades at $43.48 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 5.7× Dicks Sporting Goods Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| DKS | SNY | |
|---|---|---|
Market Cap | $18.35B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $52.34 |
52-Week Low | $187.78 | $41.33 |
Enterprise Value | $25.14B | $124.19B |
Dividend Yield | 2.44% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dick's Sporting Goods (DKS) trades at $201.95, down 5.67% in the past 24 hours, with technical indicators showing a bearish trend and key support at $198. Fundamentally, the company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.90 beating expectations, and maintains solid profitability with a 32.21% gross margin and 20.9% ROE. Recent news highlights analyst upgrades and positive coverage, while the company announced a $1.25 dividend payable in June 2026.
The outlook for DKS is mixed; analyst consensus is bullish with a $263.22 price target and no sell ratings, but technical weakness and a recent decline pose near-term risks. Investment opportunities include undervaluation based on a P/E of 19.96 and accelerating sales growth, while risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder litigation news.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
